Product Information
ABACAVIR-LAMIVUDINE 600-300 MG is a generic product labeled by Cipla USA Inc., priced at $1.4688 per EA under NDC 69097036202. Its NADAC has been published 484 times since May 17, 2017.
FDA first approved this application on Mar 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600; 300 mg/1; mg/1
Manufacturer
Cipla USA Inc.NDC
69097036202
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ABACAVIR SULFATE; LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA091144FDA Approved
3/28/2017
TE Code
AB
On Market Since
3/28/2017
Pharmacological Classes
Price Statistics
The NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has been published 484 times since May 17, 2017, and over the history we have for it it has declined 92.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4688 per EA |
|---|---|
| All-time high | $20.2246 (Jun 14, 2017) |
| All-time low | $1.2091 (Nov 22, 2023) |
| 52-week high | $1.6284 |
| 52-week low | $1.2621 |
| Median price | $2.1408 |
| Average price | $2.6011 |
| Largest weekly change | -66.0% (Jun 21, 2017) |
| Weeks tracked | 484 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Abacavir and lamivudine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ABACAVIR-LAMIVUDINE 600-300 MG?
The current National Average Drug Acquisition Cost (NADAC) for ABACAVIR-LAMIVUDINE 600-300 MG, manufactured by Cipla USA Inc., is $1.4688 per EA (NDC 69097036202), effective Aug 19, 2026.
How has the price of ABACAVIR-LAMIVUDINE 600-300 MG changed over time?
Over the history we have for it, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has declined 92.7%. It has been tracked across 484 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for ABACAVIR-LAMIVUDINE 600-300 MG?
Since May 17, 2017, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has ranged from a low of $1.2091 (Nov 22, 2023) to a high of $20.2246 (Jun 14, 2017), with a median of $2.1408 per EA.
Are there cheaper alternatives to ABACAVIR-LAMIVUDINE 600-300 MG?
No other NADAC-published product currently shares the active ingredient and strength of ABACAVIR-LAMIVUDINE 600-300 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ABACAVIR-LAMIVUDINE 600-300 MG?
ABACAVIR-LAMIVUDINE 600-300 MG (NDC 69097036202) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.